HC Wainwright & Co. Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $55
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and set a price target of $55.
July 22, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on AnaptysBio with a Buy rating and a price target of $55, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $55 by HC Wainwright & Co. is likely to positively impact AnaptysBio's stock price in the short term as it reflects a strong endorsement from a reputable analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100